L‑type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer

Hayase,Suguru; Kumamoto,Kensuke; Saito,Katsuharu; Kofunato,Yasuhide; Sato,Yu; Okayama,Hirokazu; Miyamoto,Kotaro; Ohki,Shinji; Takenoshita,Seiichi

doi:10.3892/ol.2017.7148

L‑type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer

Authors:
- Suguru Hayase
- Kensuke Kumamoto
- Katsuharu Saito
- Yasuhide Kofunato
- Yu Sato
- Hirokazu Okayama
- Kotaro Miyamoto
- Shinji Ohki
- Seiichi Takenoshita
View Affiliations

Affiliations: Department of Organ Regulatory Surgery, Fukushima Medical University School of Medicine, Fukushima, Fukushima 960‑1295, Japan
Published online on: October 6, 2017 https://doi.org/10.3892/ol.2017.7148
Pages: 7410-7416

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown that the L‑type amino acid transporter 1 (LAT1) is highly expressed in many types of cancer. Upregulated LAT1 expression is considered to be associated with cancer cell proliferation. In the present study, we investigated LAT1 expression in 210 patients with colorectal cancer (CRC) and 40 patients with colonic adenoma using an immunohistochemical method, and analyzed the associations between LAT1 expression and clinicopathological factors and prognosis. The biological significance of LAT1 was also examined under conditions with sub‑normal amounts of essential amino acids using colon cancer cell lines. High expression of LAT1 was observed in 152 of 210 CRC patients (72.4%) and 12 of 40 patients with colonic adenoma (30%), and this difference in the frequency of LAT1 expression between CRC and adenoma was significant (P<0.001). High expression of LAT1 was associated with venous invasion (P=0.027). The restriction of amino acids suppressed cell proliferation in CRC cells with higher LAT1 expression, while cellular proliferation was not suppressed in the cells expressing lower levels of LAT1. Mammalian target of rapamycin (mTOR) expression was also downregulated under restricted availability of amino acids, suggesting that the restriction of amino acids induced an antitumor effect through inhibition of the LAT1/mTOR pathway. In summary, the present study demonstrated that LAT1 expression is frequently upregulated in CRC and is associated with cancer cell proliferation via the mTOR pathway.

View Figures

View References

1	Christensen HN: Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 70:43–77. 1990.PubMed/NCBI
2	Palacín M, Estévez R, Bertran J and Zorzano A: Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev. 78:969–1054. 1998.PubMed/NCBI
3	Kanai Y, Segawa H, Miyamoto Ki, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998. View Article : Google Scholar : PubMed/NCBI
4	Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, et al: Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI
5	Prasad PD, Wang H, Huang W, Kekuda R, Rajan DP, Leibach FH and Ganapathy V: Human LAT1, a subunit of system L amino acid transporter: Molecular cloning and transport function. Biochem Biophys Res Commun. 255:283–288. 1999. View Article : Google Scholar : PubMed/NCBI
6	Kim DK, Ahn SG, Park JC, Kanai Y, Endou H and Yoon JH: Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precursor lesions. Anticancer Res. 24:1671–1675. 2004.PubMed/NCBI
7	Honjo H, Kaira K, Miyazaki T, Yokobori T, Kanai Y, Nagamori S, Oyama T, Asao T and Kuwano H: Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. J Surg Oncol. 113:381–389. 2016. View Article : Google Scholar : PubMed/NCBI
8	Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H and Okayasu I: High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: Comparison with non-cancerous lesions. Pathol Int. 61:281–289. 2011. View Article : Google Scholar : PubMed/NCBI
9	Segawa A, Nagamori S, Kanai Y, Masawa N and Oyama T: L-type amino acid transporter 1 expression is highly correlated with gleason score in prostate cancer. Mol Clin Oncol. 1:274–280. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, et al: Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer. Br J Cancer. 98:742–748. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, et al: Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 13:4822013. View Article : Google Scholar : PubMed/NCBI
12	Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, et al: Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 107:632–638. 2012. View Article : Google Scholar : PubMed/NCBI
13	Furuya M, Horiguchi J, Nakajima H, Kanai Y and Oyama T: Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 103:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
14	Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell. 124:471–484. 2006. View Article : Google Scholar : PubMed/NCBI
15	Le Bihan S, Marsaud V, Mercier-Bodard C, Baulieu EE, Mader S, White JH and Renoir JM: Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin-and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. Mol Endocrinol. 12:986–1001. 1998. View Article : Google Scholar : PubMed/NCBI
16	Lin J, Adam RM, Santiestevan E and Freeman MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59:2891–2897. 1999.PubMed/NCBI
17	Luan FL, Hojo M, Maluccio M, Yamaji K and Suthanthiran M: Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation. 73:1565–1572. 2002. View Article : Google Scholar : PubMed/NCBI
18	Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, et al: L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol. 99:433–438. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, et al: L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 99:2380–2386. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ebara T, Kaira K, Saito J, Shioya M, Asao T, Takahashi T, Sakurai H, Kanai Y, Kuwano H and Nakano T: L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer. Anticancer Res. 30:4223–4227. 2010.PubMed/NCBI
21	Martins SF, Amorim R, Mota SC, Costa L, Pardal F, Rodrigues M and Longatto-Filho A: Ki-67 expression in crc lymph node metastasis does not predict survival. Biomed Res Int. 2015:1316852015. View Article : Google Scholar : PubMed/NCBI
22	Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N and Wieand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol. 21:241–250. 2003. View Article : Google Scholar : PubMed/NCBI
23	Jansson A and Sun XF: Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS. 105:730–734. 1997. View Article : Google Scholar : PubMed/NCBI
24	Shi L, Luo W, Huang W, Huang S and Huang G: Downregulation of L-type amino acid transporter 1 expression inhibits the growth, migration and invasion of gastric cancer cells. Oncol Lett. 6:106–112. 2013.PubMed/NCBI
25	Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, et al: Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69:4918–4925. 2009. View Article : Google Scholar : PubMed/NCBI
26	Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H and Kanai Y: Identification and functional characterization of a Na⁺-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 274:19745–19751. 1999. View Article : Google Scholar : PubMed/NCBI
27	Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, et al: Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 136:521–534. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C and Avruch J: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 273:14484–14494. 1998. View Article : Google Scholar : PubMed/NCBI
29	Wang X, Campbell LE, Miller CM and Proud CG: Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem J. 334:261–267. 1998. View Article : Google Scholar : PubMed/NCBI
30	Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y and Endou H: L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 101:173–179. 2010. View Article : Google Scholar : PubMed/NCBI
31	Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, et al: Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: A clinicopathologic study. Clin Cancer Res. 13:6369–6378. 2007. View Article : Google Scholar : PubMed/NCBI